These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8102561)

  • 1. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
    Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
    Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
    Ross DD; Wooten PJ; Tong Y; Cornblatt B; Levy C; Sridhara R; Lee EJ; Schiffer CA
    Blood; 1994 Mar; 83(5):1337-47. PubMed ID: 8118035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
    den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells.
    Hegewisch-Becker S; Faltz C; Hossfeld DK
    Eur J Haematol; 1996; 56(1-2):12-22. PubMed ID: 8599988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
    Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
    Nooter K; Sonneveld P; Oostrum R; Herweijer H; Hagenbeek T; Valerio D
    Int J Cancer; 1990 Feb; 45(2):263-8. PubMed ID: 1968051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.
    Van Acker KL; Van Hove LM; Boogaerts MA
    Cytometry; 1993 Oct; 14(7):736-46. PubMed ID: 7902231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
    Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
    Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
    Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia.
    Hart SM; Ganeshaguru K; Lyttelton MP; Prentice HG; Hoffbrand AV; Mehta AB
    Leuk Lymphoma; 1993 Oct; 11(3-4):239-48. PubMed ID: 7903178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
    Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ
    Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.
    Marie JP; Faussat-Suberville AM; Zhou D; Zittoun R
    Leukemia; 1993 Jun; 7(6):825-31. PubMed ID: 8099135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.
    Ross DD; Joneckis CC; Schiffer CA
    Blood; 1986 Jul; 68(1):83-8. PubMed ID: 3719105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
    Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
    Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
    Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
    Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
    Berman E; McBride M
    Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.